Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia

Texto completo
Autor(es):
Mostrar menos -
Junqueira Reis, Luiza Cunha ; Picanco-Castro, Virginia ; Martins Fernandes Paes, Barbara Cristina ; Pereira, Olivia Ambrozini ; Gyuricza, Isabela Gerdes ; de Araujo, Fabiano Tofoli ; Morato-Marques, Mariana ; Moreira, Lilian Figueiredo ; Oliveira Costa, Everton de Brito ; Moreira dos Santos, Tylita Pollyanna ; Covas, Dimas Tadeu ; Pereira Carramaschi, Lygia da Veiga ; de Sousa Russo, Elisa Maria
Número total de Autores: 13
Tipo de documento: Artigo Científico
Fonte: STEM CELLS INTERNATIONAL; 2017.
Citações Web of Science: 2
Resumo

Sickle cell anemia (SCA) is a monogenic disease of high mortality, affecting millions of people worldwide. There is no broad, effective, and safe definitive treatment for SCA, so the palliative treatments are the most used. The establishment of an in vitro model allows better understanding of how the disease occurs, besides allowing the development of more effective tests and treatments. In this context, iPSC technology is a powerful tool for basic research and disease modeling, and a promise for finding and screening more effective and safe drugs, besides the possibility of use in regenerative medicine. This work obtained a model for study and treatment of SCA using iPSC. Then, episomal vectors were used for reprogramming peripheral blood mononuclear cells to obtain integration-free iPSC. Cells were collected from patients treated with hydroxyurea and without treatment. The iPSCP Bscd lines were characterized for pluripotent and differentiation potential. The iPSC lines were differentiated into HSC, so that we obtained a dynamic and efficient protocol of CD34+CD45+ cells production. We offer a valuable tool for a better understanding of how SCA occurs, in addition to making possible the development of more effective drugs and treatments and providing better understanding of widely used treatments, such as hydroxyurea. (AU)

Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
Beneficiário:Dimas Tadeu Covas
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs